U10 Full Member Application Affiliated with SWOG

描述（由申请人提供）： 德克萨斯大学医学部安德森癌症中心（MDACC）是德克萨斯州3个NCI指定的癌症中心之一（也是唯一一个指定为综合癌症中心）。MDACC通过13个跨学科护理中心为癌症患者提供综合服务，根据疾病部位/类型整合肿瘤内科、外科、放射肿瘤科、护理、药理学和其他护理提供者。在上一个授予期间，U10的领导层已经无缝过渡到国际公认的临床研究者和胸/头颈肿瘤学家Roy Herbst博士，前U10主席Scott Lippman博士继续参与MDACC SWOG执行委员会。如本提案所述，MDACC在上一个资助期内表现出越来越多的科学贡献，20名MDACC研究人员被列为42份单独手稿的主要作者或共同作者，30份摘要在本资助期内出版或提交出版。此外，在上一个赠款期间，20名调查员担任了23项试验的协调员/共同协调员，目前正在制定6项方案/方案概念。MDACC也显示出逐年增加的应计费用，2008年有90名患者应计费用，导致所有SWOG研究中心的平均应计费用达到前三分之一。在本报告所述期间，对SWOG领导层的贡献仍然强劲; 8名研究者目前在SWOG担任领导职务，另有5名研究者在上一个资助期担任领导职务，从而使我们能够通过放射肿瘤学家，外科医生和病理学家参与SWOG领导职务，为SWOG提供多学科的专业知识和资源。该中心在其工作人员的大力投入下，还制定了合作社支助服务倡议，以确保在机构一级了解和遵守合作社报告要求。最后，其他贡献包括在选择，PCPT，HIGPN和其他委员会的领导角色; MDACC教师在小组会议上的五次演讲;以及即将与RTOG进行的小组间合作等。MDACC SWOG计划的未来计划包括为初级教师扩展我们的SWOG辅导计划。MDACC将继续发挥其优势，在SWOG环境中开发多学科，创新的II期和III期研究。我们期待着领导SWOG在癌症研究，治疗和预防方面的努力，从而实现我们在德克萨斯州，国家和世界消除癌症的使命。 相关性：通过参与癌症临床试验合作小组，协助开展癌症研究，并发现创新的癌症治疗方案。 主要经销商： 自上一个赠款期以来，MDACC已将领导权移交给Roy Herbst博士，而Scott Lippman博士仍留在执行委员会，以提供连续性和建议。 Drs Herbst和Hogue是MD安德森在各自领域的知名领导者，他们与其他U10研究人员一起沿着，为这一应用提供了主要优势。 人类受试者保护（简历）：可接受 没有明显的担忧。 女性入选（简历）：可接受 没有明显的担忧。 列入少数群体名单（简历）：可接受 少数族裔，特别是西班牙裔的应计费用需要注意。 入选儿童（简历）：可接受 入组的受试者通常为18岁或以上。 总体建议： 此应用程序得分为35，并建议提供六年的支持。

DESCRIPTION (provided by applicant): The University of Texas, MD Anderson Cancer Center (MDACC) is one of 3 NCI-designated cancer centers in Texas (and the only one designated as a Comprehensive Cancer Center). MDACC provides comprehensive services to cancer patients through 13 interdisciplinary care centers, integrating medical oncology, surgery, radiation oncology, nursing, pharmacology, and other care providers by disease site/type. During the previous granting period, U10 leadership has been seamlessly transitioned to an internationally recognized clinical investigator and thoracic/head and neck oncologist, Dr. Roy Herbst, with the continued involvement of the former U10 Chair, Dr. Scott Lippman, in the MDACC SWOG Executive committee. As documented in this proposal, MDACC has demonstrated increasing scientific contributions in the previous grant period, with 20 MDACC investigators listed as either primary author or co-author on 42 separate manuscripts and 30 abstracts either published or submitted for publication during this grant period. In addition, 20 investigators have served as either coordinator/co-coordinator of 23 trials in the last grant period, with 6 protocol/protocol concepts currently under development. MDACC has also exhibited year-over-year accrual increases, with 90 patients accrued in 2008, leading to an average accrual in the top third of all SWOG sites. Contributions to SWOG leadership have remained robust over the reporting period; 8 investigators currently hold leadership roles in SWOG, with an additional 5 investigators having held leadership positions in the previous grant period, thus allowing us to provide our multidisciplinary expertise and resources to SWOG, through the involvement of radiation oncologists, surgeons, and pathologists in SWOG leadership positions. MDACC, with significant input from MDACC SWOG staff, also created a Cooperative Group Support Services initiative to ensure awareness of and compliance with cooperative group reporting requirements at an institutional level. Finally, additional contributions include leadership roles in SELECT, PCPT, HIGPN, and other committees; five presentation given by MDACC faculty at Group meetings; and forthcoming intergroup collaborations with RTOG, among others. Future plans for the MDACC SWOG program include the expansion of our SWOG mentoring program for junior faculty. MDACC will continue to apply its strengths in developing multidisciplinary, innovative Phase II and III studies within the SWOG setting. We look fonward to leading SWOG efforts in cancer research, treatment, and prevention; thereby fulfilling our mission of eliminating cancer in Texas, the nation, and the world. RELEVANCE: To assist the conduct of cancer research, through participation in a cancer clinical trials cooperative group, and discover innovative cancer treatment options. PRINCIPAL INVESTIGATOR: Since the prior grant period, the MDACC has transitioned leadership to Dr. Roy Herbst while Dr. Scott Lippman has remained on the Executive Committee to provide continuity and advice. Drs Herbst and Hogue are well established leaders at MD Anderson in their respective fields, who along with the other U10 investigators, provide major strength to this application. PROTECTION OF HUMAN SUBJECTS (Resume): ACCEPTABLE No concerns are evident. INCLUSION OF WOMEN PLAN (Resume): ACCEPTABLE No concerns are evident. INCLUSION OF MINORITIES PLAN (Resume): ACCEPTABLE Accrual of minorities, especially Hispanics, needs attention. INCLUSION OF CHILDREN PLAN (Resume): ACCEPTABLE Enrolled subjects are generally 18 years of age or older. OVERALL RECOMMENDATION: This application is scored 35 and is recommended for six years of support.